Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

• Published in: Hematology, Transfusion and Cell Therapy Vol. 43; no. Suppl 2; pp. S13 - S21
• Main Authors: Seber, Adriana, de Castro Junior, Claudio Galvão, Kerbauy, Lucila N., Hirayama, Alexandre V., Bonfim, Carmem, Fernandes, Juliana Folloni, Souza, Mair, Schafell, Rony, Nabhan, Samir, Loggetto, Sandra Regina, Simões, Belinda Pinto, Rocha, Vanderson, de Lima, Marcos, Guerino-Cunha, Renato L., Bittencourt, Henrique
• Format: Journal Article
• Language: English
• Published: Elsevier España, S.L.U 01.11.2021; Sociedade Brasileira de Hematologia e Hemoterapia; Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH); Elsevier
• Subjects: Acute lymphoblastic leukemia; Acute lymphoid leukemia; Adoptive cellular therapy; Advanced cellular therapy; Car-T cells; Cellular therapy; Immunotherapy; MEDICINE, GENERAL & INTERNAL; Special; Acute lymphoblastic leukemia; Immunotherapy; Advanced cellular therapy; Cellular therapy; Car-T cells; Acute lymphoid leukemia; Adoptive cellular therapy
• ISSN: 2531-1379; 2531-1387; 2531-1387
• DOI: 10.1016/j.htct.2021.09.002

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.